Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

According to our protocol, we compared tumor volumes on treatment day 44 (that was the last day that both groups had at least four tumor measurements) and found the average tumor volume of the rapamycin plus sorafenib treated group (1820 ± 245 mm 3 , n = 5) was smaller than the average tumor volume of the rapamycin treated group (2607 ± 247 mm 3 , n = 4); this difference approaches statistical significance (p = 0.06).

also in 141 other papers